Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Aspirin plus a DOAC may do more harm than good in some

Key clinical point: Adding aspirin to DOAC therapy for secondary prevention of VTE or prevention of stroke associated with NVAF may increase bleeding risk.

Major finding: Bleeding event rate per 100 patient years: 39.50 vs. 32.32 with DOAC + aspirin vs. DOAC alone.

Study details: A registry-based cohort study of 639 patients and 639 controls.

Disclosures: Dr. Schaefer reported having no disclosures.

Citation:

Schaefer J et al. ASH 2019. Abstract 787.